La cadena de opciones muestra datos clave de las opciones de acciones de Brainstorm Cell a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Brainstorm Cell..

Brainstorm Cell (NASDAQ:BCLI) Bolsa, Cadena de Opciones

Brainstorm Cell

Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell Therapeutics Inc

BrainStorm Cell Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it has received Notice of Allowance from the U.S. Patent &amp; Trademark Office (USPTO) for patent application 16/981,757 which covers its proprietary exosome technology.&nbsp;

News

BCLI

BrainStorm Receives Notice Of Allowance fFr U.S. Patent On Innovative Exosome Platform Technology

Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.57) by 10.53 percent.

Earnings

Earnings Beats

Brainstorm Cell Q3 2024 GAAP EPS $(0.51) Beats $(0.57) Estimate

WIIM

PLUR

Brainstorm Cell Therapeutics and Pluri shares are trading higher after the companies entered into a memorandum of understanding to manufacture NurOwn for a Phase 3b trial in amyotrophic lateral sclerosis.

This MOU enables BrainStorm to begin transfer of its manufacturing technology and start producing NurOwn at Pluri's manufacturing facility upon finalizing the binding definitive agreement.

Contracts

BrainStorm Enters Memorandum Of Understanding With Pluri To Manufacture NurOwn For Use In Planned Phase 3b Trial In Amyotrophic Lateral Sclerosis

Biotech

Health Care

General

Brainstorm Cell Therapeutics Received Written Notice From The Nasdaq Stock Market Stating That The Company Has Regained Compliance With The Minimum Closing Bid Price Requirement For Continued Listing

BrainStorm Cell Therapeutics Announced The Presentation Of Two Posters Featuring Nurown (MSC-NTF0 Or Debamestrocel) At The 2024 Annual Northeastern Amyotrophic Lateral Sclerosis Consortium Meeting

Brainstorm Cell Therapeutics shares are trading higher after the company announced its CEO will discuss its Phase 3b ALS trial at the Maxim Healthcare virtual summit.

BrainStorm Cell Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced its participation in the 2024 Maxim Healthcare Virtual Summit. Chaim Lebovits, President and CEO of BrainStorm, will join Jason McCarthy, Ph.D., Senior Managing Director and Head of Biotechnology Research at Maxim Group, for a Fireside Chat at 9:30 a.m. ET on October 15. During the session, Mr. Lebovits will provide an update on the planned Phase 3b clinical trial for NurOwn&#xAE;, the company's investigational cell therapy for ALS. This event presents a valuable opportunity to engage with the investment community and share in-depth insights into the upcoming trial.
&nbsp;
The Maxim Healthcare Summit will take place from October 15 to 17 and will bring together biotechnology, diagnostic, medical device, and healthcare information technology companies. Senior analysts will lead presentations and discussions, while engaging industry panels will focus on critical healthcare trends shaping the future of the industry.

BrainStorm CEO to Discuss Phase 3b ALS Trial at Maxim Healthcare Virtual Summit

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

<h3>Gainers</h3>
<ul>
<li>IGC Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IGC#AMEX">IGC</a>) stock moved upwards by 10.7% to $0.39 during Friday's after-market session. The company's market cap stands at $29.6 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares rose 10.03% to $5.92. The market value of their outstanding shares is at $3.0 million. </li>
<li>OptiNose (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTN#NASDAQ">OPTN</a>) stock rose 5.86% to $0.74. The company's market cap stands at $111.5 million. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) stock rose 5.07% to $0.23. The company's market cap stands at $18.6 million. </li>
<li>23andMe Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) stock moved upwards by 4.72% to $0.31. The market value of their outstanding shares is at $155.9 million. </li>
<li>Elevation Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) shares rose 4.66% to $0.62. The market value of their outstanding shares is at $36.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Gain Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) stock fell 9.6% to $1.8 during Friday's after-market session. The market value of their outstanding shares is at $45.9 million. </li>
<li>Estrella Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLA#NASDAQ">ESLA</a>) stock declined by 6.53% to $1.11. The company's market cap stands at $40.4 million. As per the news, the Q4 earnings report came out today. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock decreased by 6.1% to $0.46. The market value of their outstanding shares is at $35.7 million. </li>
<li>Kintara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) stock declined by 6.07% to $0.19. The market value of their outstanding shares is at $10.6 million. </li>
<li>Jin Medical International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) stock decreased by 5.66% to $2.67. The company's market cap stands at $417.9 million. </li>
<li>Viracta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRX#NASDAQ">VIRX</a>) shares decreased by 5.41% to $0.21. The market value of their outstanding shares is at $8.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ELEV

ESLA

EYEN

GANX

Kintara Therapeutics, Inc. - Common Stock

KTRA

OPTN

TCBP

VIRX

ZJYL

12 Health Care Stocks Moving In Friday's After-Market Session

BrainStorm Cell Therapeutics Plans To Share Latest Update On NurOwn At This Year's NEALS Meeting

Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 69.23 percent increase over losses of $(0.13) per share from the same period last year.

Brainstorm Cell Q2 2024 GAAP EPS $(0.04), Inline. Cash And Equivalents Of $3.5M

CMC FDA Questions Resolved, PIIIb Rollout Begins, $4M Raised, Commercialization Team In Place; Signed CRO And Lined Up Commercial Manufacturer; Despite ~5% Value Range Reduction Due To Dilution, Investment Hypothesis Remains &gt;10x Return; Exploring Non-Dilutive Grant Funds

BrainStorm Cell Therapeutics Updates On NurOwn Stem Cell Therapy For ALS

BrainStorm Cell Therapeutics Says On July 18, Received MVLS Deficiency Notice From Nasdaq Listing Qualifications Department Staff

Maxim Group analyst Jason McCarthy upgrades Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) from Hold to Buy and announces $2 price target.

Upgrades

Price Target

Analyst Ratings

Maxim Group Upgrades Brainstorm Cell to Buy, Announces $2 Price Target

Offerings

BrainStorm Cell Therapeutics Prices $4.0M Registered Direct Offering Of 11,111,111 Shares At $0.36/Share

BrainStorm Cell Therapeutics Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced it has reached alignment with the U.S. Food and Drug Administration (FDA) on the Chemistry, Manufacturing, and Controls (CMC) aspects of Brainstorm's Phase 3b clinical trial for NurOwn&#xAE;, its investigational therapy for amyotrophic lateral sclerosis (ALS).

BrainStorm Cell Therapeutics Reaches Alignment With FDA On Chemistry, Manufacturing, And Control Aspects Of Phase 3b NurOwn Clinical Trial For Amyotrophic Lateral Sclerosis

BrainStorm Cell Therapeutics Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of&nbsp;Hartoun Hartounian Ph.D. as its new EVP and COO, effective as of&nbsp;June 18, 2024.
<img alt="BrainStorm Logo" src="https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg" />
Dr. Hartounian brings a distinguished track record with over 32 years of experience in the biopharmaceutical industry, with a focus on cell and gene therapy. His career highlights include founding and leading BioCentriq, a state-of-the-art cell and gene therapy CDMO facility, which was successfully acquired for&nbsp;$73 million&nbsp;in 2022. Dr.&nbsp;Hartounian founded and managed the growth of four biotechnology companies. He has a track record of achieving aggressive goals at large pharmaceutical, contract development and manufacturing organizations, as well as at start-up biotechnology companies.
In his new role, Dr. Hartounian will oversee all operational aspects of BrainStorm Cell Therapeutics, including CMC and commercialization. He has the right skillset to enhance the company&#39;s operational efficiency and the strategic vision to support the commercial readiness of its therapeutic platforms including NurOwn&reg; for amyotrophic lateral sclerosis (ALS).

Management

BrainStorm Cell Therapeutics Taps Haro Hartounian Ph.D. as COO, Effective June 18

<h3>Gainers</h3>
<ul>
<li>Kineta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KA#NASDAQ">KA</a>) shares moved upwards by 28.5% to $0.67 during Friday's after-market session. The company's market cap stands at $8.1 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) stock moved upwards by 13.99% to $0.57. The market value of their outstanding shares is at $5.6 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) shares moved upwards by 11.0% to $0.12. The market value of their outstanding shares is at $1.9 million. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) shares increased by 9.08% to $0.51. The market value of their outstanding shares is at $35.9 million. </li>
<li>Bullfrog AI Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRG#NASDAQ">BFRG</a>) stock increased by 7.53% to $2.71. The company's market cap stands at $21.2 million. </li>
<li>Can Fite Biofarma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CANF#AMEX">CANF</a>) stock increased by 7.46% to $3.6. The company's market cap stands at $17.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) stock decreased by 12.4% to $0.78 during Friday's after-market session. The market value of their outstanding shares is at $5.8 million. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) shares fell 11.47% to $3.09. The market value of their outstanding shares is at $1.7 million. </li>
<li>Ontrak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) stock declined by 7.45% to $0.23. The company's market cap stands at $11.0 million. </li>
<li>AN2 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANTX#NASDAQ">ANTX</a>) stock declined by 7.38% to $2.01. The company's market cap stands at $59.9 million. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares decreased by 6.03% to $0.36. The company's market cap stands at $5.3 million. </li>
<li>Renovaro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>) stock decreased by 5.49% to $1.55. The company's market cap stands at $228.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANTX

BFRG

CANF

CERO

ISPC

NDRA

OTRK

RENB

SCNI

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Brainstorm Cell Therapeutics (BCLI – Research Report), retaining the price target ...

Buy Rating Affirmed for Brainstorm Cell Therapeutics Amid Strategic Advances and Robust Financials

Brainstorm Cell Therapeutics ( ($BCLI) ) has issued an update. Brainstorm Cell Therapeutics Inc. stockholders have given the green light to signifi...

Brainstorm Cell Therapeutics Enacts Key Corporate Changes

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Brainstorm Cell Therapeutics (BCLI – Research Report). The associated pri...

Strong Buy Recommendation for Brainstorm Cell Therapeutics Amid Positive Clinical Developments and Strategic FDA Milestones

Brainstorm Cell Therapeutics ( ($BCLI) ) has issued an announcement. Brainstorm Cell Therapeutics, Inc. has released a presentation highlighting it...

Brainstorm Therapeutics Advances NurOwn® Phase 3b Trials

BrainStorm (BCLI) announced the presentation of two posters featuring NurOwn at the 2024 Annual Northeastern Amyotrophic Lateral Sclerosis Consorti...

BrainStorm presents NurOwn survival data at NEALS Meeting

BrainStorm Cell Therapeutics regains compliance with Nasdaq

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Brainstorm Cell Therapeutics (BCLI – Research Report). T...

Brainstorm Cell Therapeutics (BCLI) Receives a Buy from Maxim Group

BrainStorm Cell Therapeutics GAAP EPS of -$1.80

BrainStorm (BCLI) Cell Therapeutics announced that it has received Notice of Allowance from the U.S. Patent & Trademark Office for patent applicati...

BrainStorm receives Notice of Allowance for patent on exosome technology

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Opus Genetics (IRD – Research Report) and Brainstorm...

Comments

Brainstorm Cell

Brainstorm Cell (BCLI) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL